Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation

Title: Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation Agency: U.S. Food and Drug Administration (FDA) Notice Type: Presolicitation: Firm-Fixed Price DEA surveillance data show that street fentanyl is frequently adulterated with xylazine, d-methamphetamine, or alprazolam — each of which induces respiratory depression through a distinct mechanism. Approximately 80% of opioid overdose case…